In a recent study not yet announced it was found that Veltassa works on hemorrhoids. Mine have never been so big. What the bull? Sentiment and rumor!
Fiction message dare if I do not spell it out for some.
They converting long holders into Veltassa users. That is the plan. To annihilate the longs so they get sick enough and start popping veltassa poppers as they would valium. Makes about as much sense as anything else that has been going on of late. For now as longs. We can use our RLYP certificates to wipe our back sides.
Now that I said all that #$%$ out of frustration above. I feel better. It is called therapy. I think I am loose enough to go to the bathroom now. Thanks everyone.
Sentiment: Strong Buy
I agree the short interest has not let up. Been very harsh no matter what the surrounding event conditions are. Just how would these shorts all come together especially after the company has an approval of their product makes no sense.
Who is going to immediately dish out the cash to bring the equipment up to standard? Will not happen overnight. The equipment could have been faulty during the trials. Which would definitely red flag the outcome. Will need a whole new trial? AZN is not talking on the total subject for now. I am sure something will unfold one way or another. Investors will eventually start asking questions. Opinion.
Just a matter of time that the RLYP board presents investors with their buy out decision/recommendation. My opinion.
8 times is a massive amount. When short interest is 2 to 3 times that of the daily volume. It usually starts a short squeeze in my opinion. 8 times the daily volume is massive.
Just a hunch, but in comparison RLYP was also late in the day by FDA for approval with a warning label. So maybe a warning label is being processed? Just tossing out a thought.
I am on the FDA site and do not find the TTNP drug being mentioned for today. what is the link?
The FDA posts first. How the company handles it thereafter is their business. No one has the jump on the information, not even the company. If that was the case there be a blood bath.
You maybe very correct on the long term. Creating a repeated pattern of hypertension in an already afflicted patient is a serious concern. Could go as far and not approve until the long term data is provided. Watching like the rest of the audience is.
Label revision is a very common practice for companies and the FDA. Why RLYP was so harshly treated by the investment community was because of ignorance knowing how drugs get approved. Also how drugs are revised thereafter.
The company has no control on the release of the results. The FDA issues the information publicly at anytime during the day/evening/night.
So far the shorts have had the right call. Time and time again.
Will the longs get blistered again? Tune in tomorrow!